54 results about "Azoospermia" patented technology

A formulation for male contraception comprising a progestin possessing both estrogenic and androgenic properties is remarkably effective for spermatogenesis suppression in males. The progestin Norethisterone (NET), particularly its derivatives Norethisterone acetate and Norethisterone enanthate in sufficient doses induce oligozoospermia or azoospermia in males. Formulations further comprising an androgen, such as a testosterone derivative such as a testosterone ester, particularly testosterone undecanoate, are especially effective male contraceptive formulations.

The invention discloses seminal plasma piRNA markers or their combination for detecting and/or predicting male reproductive dysfunction and application thereof. The piRNA markers or their combination are 61 in quantity and mainly include piR-31068, piR-31925, piR-43771, piR-43773 and piR-30198; this combination can be used to detect and/or predict asthenospermia and azoospermia. In the invention, seminal plasma is easy to obtain, no other tissues are required, and examinations are noninvasive; seminal plasma piRNA can indicate pathological and biological conditions of a whole spermatogenic stage, accuracy level of detection can be increased using the seminal plasma piRNA as auxiliary detection indexes, the pathological and biological conditions the whole spermatogenic process are indicated on molecular level, and a latent target is provided for the diagnosis and treatment of male reproductive dysfunction.

The invention discloses a trace sperm cryopreservation carrier and corresponding freezing and thawing methods thereof. The trace sperm cryopreservation carrier is in a rectangular, square or circular horizontal or groove shape and is made of a transparent plastic or transparent glass, and the size of the trace sperm cryopreservation carrier can bear 1-3 0.1-10.0 mu L freezing liquid micro drops. The freezing and thawing method comprises the following steps: after preparing the freezing liquid micro drops on the trace sperm cryopreservation carrier, inserting the trace sperm cryopreservation carrier into a sperm culture dish covered with oil, grabbing sperms by a microinjection needle, putting into the freezing liquid micro drops, taking out the cryopreservation carrier, soaking up mineral oil by virtue of an absorbent paper, rapidly freezing, directly inserting the cryopreservation carrier into an ICSI vessel when thawing, and thawing the sperms by utilizing the mineral oil with the temperature of 37 DEG C. According to the trace sperm cryopreservation carrier and the corresponding freezing and thawing method thereof disclosed by the invention, as the cryopreservation carrier is inserted into the sperm culture dish covered with oil, and the sperms are grabbed and frozen, a special moisture retention device is not needed, and evaporation of the freezing liquid micro drops is not needed to be worried about; the operation is very simple, the flexibility and reliability of assisted reproductive treatment for a patient with azoospermia are greatly improved, the sperm recovery rate can reach 100 percent, and the sperm viability is about 60 percent.

The invention provides a kit for male azoospermia diagnosis and a use method. The kit contains biological marker detection reagents for measuring different expression levels of plasma miR-15b, and azoospermia is prompted by excessive expression of the miR-15b. Tiny RNA (ribonucleic acid) genes miR-15b playing an important role in the sperm generation process are discovered, the miR-15b is differently expressed in male infertility patients, and significant expression change of the miR-15b can be detected in the plasma. Based on the principle of quantitative PCR (polymerase chain reaction), and the kit is fine in result repeatability, objective, accurate and easily popularized in different detection mechanisms, hospital laboratories, male laboratories and the like.

The invention provides a sperm promoting capsule, which has the functions of nourishing kidney and yin, as well as warming yang and promoting sperms, and has excellent effect for mainly treating small semen volume or liquefaction deficiency, azoospermia, dead sperms or oligozoospermia and other symptoms caused by deficiency of kidney-yin. The capsule is prepared from the following 32 raw medicinal materials by weight: raw rehmmania, prepared rehmmania, common yam rhizome, mulberry, cistanche, Chinese angelica, astragalus membranaceus, dodder, fructus lycii, raspberry, schisandra chinensis, glossy privet fruit, morinda officinalis, epimedium and the like. The sperm promoting capsule has an excellent effect for treating small semen volume or liquefaction deficiency, azoospermia, dead sperms or oligozoospermia and other symptoms caused by deficiency of kidney-yin, and does not have side effect on human bodies due to the purely natural traditional Chinese medicinal components.

The invention relates to a three-dimensional inducing method for inducing a spermatogonia stem cell to differentiate into a functional sperm cell in vitro, and belongs to the field of bioengineering. On the basis of acquiring the spermatogonia stem cell, a three-dimensional culture system is established through Matrigel, a key factor for inducing differentiation is added, the spermatogonia stem cell is induced to differentiate in vitro to obtain the sperm cell having a fertilization ability, the sperm cell obtained through induction is identified through an immunocytochemical method, the chromosome number of the sperm cell obtained through induction is detected through fluorescence in situ hybridization (FISH), and the fertilization ability and the viability of the sperm cell obtained through induction are detected through round spermatid injection (ROSI). The application provides an excellent model for the molecular mechanism of the human sperm, and in addition, a functional gamete is provided for an azoospermia patient, so that a male infertility patient can have a child of his own.

The invention relates to a biomarker, and particularly relates to a serum miRNA biomarker composition and an application thereof. The serum miRNA biomarker composition comprises at least one miRNA and sequences of reverse transcription primers, forward primers and reverse primers of all miRNAs. The serum miRNA biomarker composition can be used for preparing oligozoospermia and azoospermia detection reagents. An oligozoospermia and azoospermia detection kit comprises the serum miRNA biomarker composition, Taq enzyme, dNTP, MgCl2 and a PCR buffer solution. The serum miRNA biomarker composition provided by the invention has the advantages of high sensitivity, low sample consumption, wide detection range and wide linear quantitative range.

The invention relates to a method and a kit for diagnosing male infertility caused by Piwil1 gene mutation. The invention discloses a gene related to male infertility such as azoospermia, namely the Piwil1 gene. Moreover, the fact that mutation at multiple positions of the Piwil1 gene can cause the occurrence of male infertility is identified. Thus, the Piwil1 gene can be used as a target gene fordiagnosing male infertility, and also can be applied to the development for the treatment medicines effective for the diseases. According to the technical scheme, explanation is given for the mechanism that PIwIl1 participates in the histone substitution by protamine for the first time.

The invention discloses seminal plasma exosome tsRNA markers related to non-obstructive azoospermia diagnosis and application of the seminal plasma exosome tsRNA markers. The markers are tRF-Pro-AGG-003 and tRF-Val-AAC-010, the sequence of tRF-Pro-AGG-003 is SEQ ID NO.1, and the sequence of tRF-Val-AAC-010 is SEQ ID NO.2. The markers have specificity and sensitivity on non-obstructive azoospermiaand can be used for preparing a diagnostic kit for non-obstructive azoospermia. The two seminal plasma exosome markers tRF-Pro-AGG-003 and tRF-Val-AAC-010 are differentially expressed in seminal plasma of patients suffering from non-obstructive azoospermia and obstructive azoospermia, non-obstructive azoospermia can be well diagnosed, an azoospermia sperm taking result can be predicted, and the effect of the markers is superior to the indexes such as the common plasma follicle stimulating hormone level and the testicular volume.

The invention discloses a kidney-nourishing sperm-supplementing pill and a production method thereof, and the kidney-nourishing sperm-supplementing pill is characterized by comprising the following raw materials: 20-30 grams of pilose antler, 15-20 grams of cordyceps sinensis, 10-20 grams of polygonatum, 15-25 grams of dodder, 10-20 grams of cherokee rose fruit, 10-20 grams of raspberry, 10-20 grams of curculigoside, 15-25 grams of californianus, 20-24 grams of astragali complanati semen, 20-26 grams of herba epimedii, 15-19 grams of morinda officinalis, 10-20 grams of fructus psoraleae, 8-12 grams of plantago, 8-12 grams of sargentgloryvine stem, 10-14 grams of ginkgo biloba leaf, 20-26 grams of eucommia, 20-26 grams of angelica, 23-27 grams of herba cistanche and 10-12 grams of poria. The kidney-nourishing sperm-supplementing pill has the advantages that materials are scientifically carefully selected, and the kidney-nourishing sperm-supplementing pill has very good curative effect on azoospermia disease. The kidney-nourishing sperm-supplementing pill is simple in production method, convenient in raw material purchase, is a very good drug for treatment of the azoospermia disease.

The invention belongs to the field of analytical chemistry and clinical medicine, and discloses an application of lead and cadmium mixing exposure detection in an assistant diagnosis of azoospermia. An exposed biomarker associated with the azoospermia is the mixing exposure of the lead and the cadmium. The concentration of the lead and the cadmium in whole blood can be detected by ICP-MS (Inductively Coupled Plasma Mass Spectrometry), which can be used for the assistant diagnosis of the azoospermia. The application of the lead and the cadmium mixing exposure detection in the assistant diagnosis of the azoospermia has the advantages of less blood volume, simple operation, fast, accurate, and good clinical promotion value.

The invention provides a group of biomolecular markers and a kit for accurate typing of azoospermia, the molecular markers are seminal plasma exosome mRNA, and the mRNA comprises PRM2, ADAM28, WFDC13, WFDC9, SEMG2 and PSA. The seminal plasma exosome is used as a marker source and is focused to genital gland specific mRNA, and the specific mRNA expression of each part in the seminal plasma exosome is comprehensively detected, so that whether obstruction exists or not and obstruction parts or sperm collection outcome is determined. The kit disclosed by the invention is based on the RNA enrichment effect and the stability of exosomes, and is combined with seminal plasma exosome long-chain RNA template amplification and qRT-PCR detection technologies to amplify and acquire a genitalia specific mRNA signal in seminal plasma, so that the sensitivity and the stability of detection are realized.

The invention relates to a novel azoospermia pathogenic gene and an application thereof and relates to a marker for azoospermia disease and the application thereof. The novel azoospermia pathogenic gene BRDT is firstly discovered in the manner of screening in a consanguineous marriage family. After patient individuals in the family are subjected to exome sequencing and comparison on the basis of one azoospermia consanguineous marriage family as a research object, the patients are proved as carrying BRDT gene mutations. These gene mutations can be utilized to detect the azoospermia.

The invention discloses a non-obstructive azoospermia auxiliary diagnosis gene detection kit, relates to the field of azoospermia diagnosis, and solves the problem of difficult clinical diagnosis of male infertility. The non-obstructive azoospermia auxiliary diagnosis gene detection kit comprises a specific PCR primer, a PCR buffer solution, dNTPs and DNA polymerase, wherein the specific PCR primer is a group of specific primers for detecting the 69826819 mutation site in the non-obstructive azoospermia TEX11 gene. A specific primer SEQ ID NO: 1 and a specific primer SEQ ID NO: 2 are designed,the specific primers have higher specificity, the non-obstructive azoospermia auxiliary diagnosis gene detection kit consisting of the specific primers is adopted to detect the 69826819 mutation sitein the TEX11 gene of a male patient, and the detection rate of the gene mutation is 100%.

The invention discloses application of a P substance in preparation of a drug for treating male infertility. Treatment of an azoospermia mouse model by the P substance finds that the P substance can effectively improve spermatogenic functions of the azoospermia mouse model caused by busulfan and further proves that the P substance improves the spermatogenic functions by promoting proliferation ofspermatogenic cells. The invention provides a new thought and theoretical support for treatment of male infertility.

The invention discloses a male infertility related genetic marker, the sequence of which is that of the UBE2B gene. The binding site of the UBE2B gene's promoter region and the transcription factor SP1 undergoes mutation, and the mutation site is one or more of Chr.133706771T>A, Chr.133706876T>G and Chr.133706925A>G. By large-scale sequencing, four new mutation sites of the UBE2B gene's promoter region are selected from male infertility patients, a transcription factor plasmid is cotransfected into cells together with a wild type plasmid and a mutant plasmid respectively, and experiments find significant function differences and show that mutation of the UBE2B gene's promoter region is relevant to male infertility (especially azoospermia). Therefore, diagnosis detection of male infertility can be realized through the mutation.

The invention relates to the field of gene detection technology, in particular to a kit for detecting idiopathic azoospermia and a gene panel. A small amount of (3 ml) peripheral blood from a patientis utilized to extract DNA, gene mutation of the patient is detected through library-establishing, high-throughput sequencing, etc., and through bioinformatics analysis, such as mutation frequency, mutation property, biological harm and conservative property, evaluation is performed to find 30 new morbigenous genetic mutations in the patient. Only 3 ml of peripheral blood of the patient is neededfor detection and 30 detection sites are covered, thereby improving the detection rate of the mutation, and 30 sites are carried out in one reaction system, to greatly reduce the workload, improve work efficiency, and save work time.

The invention discloses a trace sperm freezing and thawing method and an automatic clamping apparatus thereof. The method comprises: S1, freezing sperms; and S2, thawing the sperms, wherein a fixing frame is placed on the bottom portion of the inner side of a liquid nitrogen box, a lifting motor is fixed on the top portion of the fixing frame, and the output shaft of the lifting motor is fixedly connected to a lifting screw rod penetrating through the fixing frame. According to the present invention, the apparatus can simultaneously freeze a plurality of freezing carrying rods, such that the operation is convenient, efficient and fast, and the sperm micro-droplets on the freezing carrying rods are subjected to uniform and accurate fumigation by the condenser so as o substantially improve the freezing resuscitation rate of the trace sperms and reduce the mistakes and the frostbite of the operator; and with the method and the apparatus, the problems that the sperm recovery is easy to fail after the sperms of paints with oligospermatism and asthenospermia, the testis sperms and the epididymal sperms are frozen in the current sperm freezing technology is well solved so as to substantially improve the assisted reproductive therapy flexibility on patients with azoospermia.

A method for treating azoospermia consists of lowering a patient's testosterone for an extended duration in order to induce spermatogonia stem cell function to produce spermatozoa. The patient's testosterone is reduced through the incorporation of glycyrrhiza glabra in three medicinal mixtures. A first medicinal mixture is used to lower testosterone in the patient as the first medicinal mixture is primarily glycyrrhiza glabra, and the first medicinal mixture is administered for at least one month. The quantity of glycyrrhiza glabra is reduced in administration of the second medicinal mixture over at least two months, subsequent to the first medicinal mixture. The quantity of glycyrrhiza glabra is further reduced in administration of the third medicinal mixture over at least three months, subsequent to the second medicinal mixture. A plurality of additional ingredients is included in the second medicinal mixture and the third medicinal mixture in order to promote spermatozoa production and virility.

The invention provides a method for directly transdifferentiating mesenchymal stem cells into sperms by using a transcription factor FOXO1, comprising the following specific steps: introducing the transcription factor FOXO1 into the mesenchymal stem cells in a transfection mode, and carrying out induced culture on the mesenchymal stem cells to obtain the sperms. According to the method, the transcription factor FOXO1 is introduced into mesenchymal stem cells, and the mesenchymal stem cells are induced to develop towards sperms, so that not only can a regulatory mechanism of the stem cells on the vital movement of the organism be known, but also a signal path for maintaining the dynamic balance of the spermatogonial stem cells SSCs is discussed, and a new scheme for inheriting biological information of a male infertility patient, especially a male azoospermia patient, is provided.

The invention relates to an application of seminal plasma BOLL to preparation of a reagent for diagnosing azoospermia meiosis arrest, and provides a reagent kit for diagnosing the azoospermia meiosisarrest. The reagent kit provided by the invention is used for detecting the expression level of BOLL in seminal plasma of a patient, so that whether sperms of a NOA patient pass through meiosis or notcan be identified, and whether the NOA patient has meiosis arrest (MA) or passes through the meiosis (non-MA) is distinguished; the meiosis arrest means that the testis of the patient does not have haploid sperms, and the testis of the NOA patient passing through the meiosis possibly has the formation of the haploid sperms, so that the microscopic sperm obtaining outcome from the testis can be indirectly forecast.

The invention relates to an azoospermia related gene Fish detection method. The human chromosome show piece is subjected to conventional pretreatment, then the situ hybridization is carried out by using a detection probe, and the existence of the azoospermia related gene is judged according to the detected fluorescence signal, wherein the detection probe is preferentially a DAZ detection probe, and the DAZ is a nucleotide sequence with the serial number of AC053490.2 of the GeneBank in the NCBI. The invention further relates to a related detection probe and a kit. The azoospermia related gene Fish detection method and the related detection probe have ingenious design, are easy to operate, can be used for detecting the azoospermia related gene rapidly, accurately and intuitively, ensure the accurate and reliable detection result which can be used as the reference for the doctor to diagnose the azoospermia and can be popularized and applied widely. The specificity and the sensitivity of the azoospermia related gene Fish detection method and the related detection probe can be improved greatly.